- Conditions
- Solid Tumors, Hematologic Malignancies, Hepatic Impairment
- Interventions
- Carfilzomib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Durham, North Carolina • Canton, Ohio + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- OT-101, mFOLFIRINOX
- Drug
- Lead sponsor
- Oncotelic Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Houston, Texas
- Conditions
- Breast Cancer, Depression
- Interventions
- Mindfulness (MAPs) Live Online, Mindfulness (MAPs) Digital App, Meditation Only Control Group
- Behavioral
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 362
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 304 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin glargine, 300 U/ml, Insulin glargine, 100 U/ml, Insulin detemir, Background Therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 407
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Guntersville, Alabama + 304 more
- Conditions
- Colorectal Cancer
- Interventions
- celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 826
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more
- Conditions
- Deep Venous Insufficiency (Diagnosis)
- Interventions
- Hancock-Jaffe bioprosthetic venous valve (VenoValve®)
- Device
- Lead sponsor
- Hancock Jaffe Laboratiores, Inc
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 24 more
- Conditions
- Heart Failure, Congestive, Ventricular Dysfunction, Cardiomyopathies
- Interventions
- Thoratec HeartMate II Left Ventricular Assist System (LVAS)
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- Not listed
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 30 more
- Conditions
- Squamous Non Small Cell Lung Cancer
- Interventions
- Open-label AZD2014, paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Detroit, Michigan • Hershey, Pennsylvania + 1 more
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Azacitidine, Entinostat, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 234
- States / cities
- Scottsdale, Arizona • Burbank, California • Los Angeles, California + 146 more
- Conditions
- Hemophilia A
- Interventions
- Not listed
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2040
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 10 more
- Conditions
- Acute Myocardial Infarction
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 2,985 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Mobile, Alabama • La Mesa, California + 76 more
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- pomalidomide, ixazomib, dexamethasone
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 336
- States / cities
- Anchorage, Alaska • Burbank, California • La Jolla, California + 237 more
- Conditions
- Central Neuropathic Pain, Multiple Sclerosis
- Interventions
- AVP-923-45, AVP-923-30, AVP-923-20, Placebo
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 44
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 40 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Dalantercept
- Biological
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 5 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 397
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- leflunomide, procarbazine hydrochloride
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- IVA337, Placebo
- Drug
- Lead sponsor
- Inventiva Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 194
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
- Conditions
- Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- gefitinib
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 43 more
- Conditions
- Type 2 Diabetes Treated With Insulin
- Interventions
- t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
- Device
- Lead sponsor
- Tandem Diabetes Care, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 19
- States / cities
- Newport Beach, California • Atlanta, Georgia • Idaho Falls, Idaho + 16 more
- Conditions
- Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Refractory Pancreatic Neuroendocrine Carcinoma
- Interventions
- Sapanisertib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 405
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 260 more
- Conditions
- Severe Traumatic Brain Injury
- Interventions
- Observational
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 25 more
- Conditions
- HCV Infection
- Interventions
- SOF, RBV, LDV/SOF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 7
- States / cities
- San Francisco, California • Miami, Florida • Chicago, Illinois + 4 more
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Echocardiography Test, Electrocardiography, Lumbar Puncture, Mesna, Methotrexate, Multigated Acquisition Scan, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more
- Conditions
- Bicep Tendon Rupture
- Interventions
- Blood Flow Restriction Therapy
- Other
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Detroit, Michigan